Summary.-Thirty-two adults with acute myeloid leukaemia (AML) were randomized to receive, from the time of diagnosis, either chemotherapy alone (C group) or chemotherapy plus Bacille Calmette-Guerin vaccine (BCG) (C + I group). After remission induction and consolidation, chemotherapy was stopped in both groups but BCG was continued in the C + I group.
reported on the efficacy of using immunotherapy in the treatment of AML, other studies have been carried out using BCG alone (Gutterman et al., 1974; Vogler & Chan, 1974; Whittaker & Slater, 1977; Vuvan et al., 1978) , BCG plus leukaemic cells (Freeman et al., 1973 ; M.R.C., 1.978), or leukaemic cells alone (Bekesi et al., 1977; Ezaki et al., 1978) . The results of 6 randomized trials of immunotherapy in AML were reviewed at a meeting of the National Cancer Institute in October 1976 (NCI, 1977 MRC, 1978) . It was concluded that immunotherapy probably does prolong survival after relapse and possibly extends the duration of first remission.
Previous studies were based on the premise that immunotherapy is best given when the tumour cell mass is low (Mathe, 1969; Mathe et al., 1969) and therefore this treatment was not started until after remission had been attained.
The aim of this trial was to determine the effect of BCG given regularly from the time of diagnosis of AML and continued as the sole form of maintenance therapy after remission induction and consolidation. Neither of these methods of using BCG has previously been assessed.
PATIENTS AND METHODS
Between October 1975 and July 1977, 32 adults wvith acute non-lymphoblastic leukaemia were entered into the trial. There were 17 males and 15 females, and their ages ranged from 18 to 65 (mean 48) years. The trial was concluded on 1 March 1979. Diagnosis. On the basis of marrow cytology and cytochemical staining techniques (Hayhoe et al., 1964) 24 patients had acute myeloblastic leukaemia, 2 had acute promyelocytic leukaemia and 6 had acute myelo-monocytic leukaemia.
Randomization.-Using Medical Research Council criteria (MRC, 1975 ) the 32 patients were prospectively stratified into 2 groups with either good or poor prognosis. Each of these groups was further subdivided using previously selected random numbers. On recombining these subgroups, two major groups were created with comparable prognostic features, one to receive chemotherapy and BCG (C + I group, 14 patients), the other chemotherapy alone (C group, 18 patients).
Induction.-This consisted of Barts Trial No. 3 chemotherapy (Crowther et al., 1973) using daunorubicin and cytosine arabinoside.
Remisston. Where possible postmortem examinations were performed on all patients.
The monthly marrows and postmortem material from patients in the BCG group were routinely cultured for M. tuberculosis and BCG.
Reinduction.-This was attempted by further administration of daunorubicin and cytosine arabinoside, provided that a total dose of 800 mg of daunorubicin had not been exceeded. If this was not successful, cytosine arabinoside was given in combination with oral thioguanine.
CNS relapse.-Diagnosis of CNS involvement was made on clinical features and examination of cerebrospinal fluid (CSF) removed by standard lumbar puncture. Smears of' CSF samples were processed in the Shandon cytocentrifuge (Drewinko et al., 1973) and stained with Wright's stain. CNS leukaemia was treated with intrathecal cytosine arabinoside, and also in one patient by administration of the drug via an implanted Omaya reservoir.
Statistical methods. -The data were analysed using Kaplan-Meier life-tables and logrank P values as described previously for the analysis of randomized clinical trials requiring prolonged observation of each patient (Peto et al., 1976 (Peto et al., , 1977 ; P values for the incidence of first and second remissions were calculated by Fisher's exact test.
RESULTS
The results are summarized in Tables I,  II & III. There were 8 first remissions out of 14 patients (57 %) in the C+I group and 7 out of 18 patients (39%) in the C group.
There were 2 second remissions out of 8 patients in the C +I group (25%) and 1 out of 7 patients in the C group (14%).
Neither of these differences in remission rate is statistically significant (P > 0.5).
The life-table estimate of the probability of survival after randomization in the two therapeutic groups is shown by Fig. 1 . The difference in overall survival between the groups is statistically significant (x2 = 4-52, P < 0.05) when analysed by the logrank test. Two patients in the C + I group remain alive, well and in remission at the end of the trial. (Crowther et al., 1973) and the results are comparable with those obtained at that time, although the results of both groups may be worse than those in more recent studies. Previous trials of immunotherapy in AML have shown that it can probably prolong survival after relapse, and possibly slightly extend first remission (NCI, 1977) . Although in this trial there was a significant increase in overall survival in the C+I group, the length of first remission was not significantly increased and, although we found increased survival following relapse, this again was not statistically significant. The MRC in its final report on immunotherapy trials in AML raised two questions which still need to be answered: "Does immunotherapy prolong first remission?" and "Does immunotherapy prolong survival after relapse?" Unfortunately, the small number of patients in this trial prevents us from drawing any firm conclusions which might help to provide a definite answer to these questions.
The time taken for patients to achieve first remission was longer in the C + I group, but the difference from the C group was not significant (x2=0 69, P>0-1).
BCG therefore did not appear to decrease the remission induction period.
The median remission length of our C + I group is comparable to that of (Powles et al., 1973) because the induction chemotherapy was identical and no maintenance chemotherapy was given, the only difference between the trials being that we gave BCG from the time of diagnosis and Freeman et al. gave BCG and leukaemic cells from the time of remission. Freeman's group obtained a mean (not median) remission length of 20 weeks, compared with 30 weeks in our trial, suggesting that BCG alone is as effective in maintaining remission as BCG plus leukaemic cells.
The incidence of CNS relapse was very much higher in our C group (71%) than in the C + I group (0%O) and produced a highly significant reduction in survival compared with patients in both groups who did not develop CNS relapse.
CNS involvement receives little attention in previous reports of the use of immunotherapy in AML. There is experimental evidence that immunotherapy with i.v. Corynebacterium parvum causes a slight but significant increase in the survival of BALB/c mice injected intracerebrally with methylcholanthrene-induced sarcoma (Osborn et al., 1975) . This finding may be relevant to the apparent protection of the CNS in our C +I group from clinically overt leukaemic infiltration. None of the patients receiving BCG suffered any complications from the treatment, and therefore BCG may offer a simple and harmless means of CNS prophylaxis, in contrast with intrathecal drugs (MRC, 1978) and cranial irradiation (Dahl et al., 1978) .
It would seem that further assessment is warranted of the use of BCG in AML in larger-scale trials in conjunction with more recent and intensive forms of chemotherapy.
